Potential inhibitors of RPS6KB2 and NRF2 in head and neck squamous cell carcinoma

Abstract

Among the major altered pathways in head and neck squamous cell carcinoma, AKT/mTORC1/S6K and NRF2/KEAP1 pathway are quite significant. The overexpression and overstimulation of proteins from both these pathways makes them the promising candidates in cancer therapeutics. Inhibiting mTOR has been in research from past several decades but the tumour heterogeneity, and upregulation of several compensatory feed-back mechanisms, encourages to explore other downstream targets for inhibiting the pathway. One such downstream effectors of mTOR is S6K2. It is reported to be overexpressed in cancers such as head and neck cancer, breast cancer and prostate cancer. In case of NRF2/KEAP1 pathway, nuclear factor erythroid 2-related factor 2 (NFE2L2 or NRF2) is overexpressed in ∼90% of head and neck squamous cell carcinoma (HNSCC) cases. It associates with poor survival rate and therapeutic resistance in HNSCC treatment. NRF2 pathway is the primary antioxidant pathway in the cell which also serves pro-tumorigenic functions, such as repression of apoptosis, cell proliferation support and chemoresistance. The aim of this work was to explore S6K2 and NRF2 and identify novel and potential inhibitors against them for treating head and neck squamous cell carcinoma. Since the crystal structure of S6K2 was not available at the time of this study, we modelled its structure using homology modelling and performed high throughput screening, molecular dynamics simulations, free energy calculations and protein-ligand interaction studies to identify the inhibitors. We identified natural compounds Crocin and Gypenoside XVII against S6K2 and Chebulinic acid and Sennoside A against NRF2. This study provides a significant in-depth understanding of the two studied pathways and therefore can be used in the development of potential therapeutics against HNSCC.

Communicated by Ramaswamy H. Sarma

Keywords:

• HNSCC
• AKT/mTORC1/S6K pathway
• NRF2/KEAP1 pathway
• RPS6KB2
• S6K2
• NRF2
• NFE2L2
• Crocin
• Gypenoside XVII
• Chebulinic acid
• Sennoside A

Acknowledgments

The authors acknowledge the support of School of Computational and Integrative Sciences, Jawaharlal Nehru University for providing all the necessary facilities for carrying out the research work.

Disclosure Statement

The authors report no conflict of interest.

Additional information

Funding

This work was supported by DST-Purse and Drugs and Pharmaceuticals Research Programme by Department of Science and Technology under Sanction Order [number VI-D&P/546/2016-17/TDT]; and first author was supported by CSIR fellowship under File No. [09/263(1132)/2017-EMR-I] to pursue Ph.D.